Pharmacy Podcast Network

Is Offering Compliance Packaging Right for Your Pharmacy? | RxSafe

Are you looking to offer compliance packaging in your community but don’t know where to start?  Or do you already have a solution, but are struggling to scale it? Join two pharmacy owners, our wholesale partners at Value Drug, and the RxSafe podcasting team as we feature pharmacists and industry insiders to discuss how your pharmacy can offer this valuable service to your patients. We'll also discuss how your business can avoid DIR fees by leveraging Medical-at-Home and address staffing problems by streamlining your workflow.Guests: Angela Stokes - Village Pharmacy of Wake ForestMargie Lydon - Value Drug Erich Cushey - Curtis Pharmacy 

LSD: Part II, The Modern Era | Neural Pharm Podcast

Evaluating literature around microdosing, drug interactions, recent clinical research, and more!
***Disclaimer: this podcast is intended for informational purposes only on the safety and efficacy data of the substances discussed. As healthcare professionals, we do not advocate for or against the use of substances which are considered illicit by the United States Drug Enforcement Administration***
References:
Bonson KR, et al. Chronic administration of serotonergic anti-depressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology. 1996; 14(6)
Gasser P, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. The Journal of Nervous and Mental Disease. 2014; 202(7): 513-520
Lopez-Gimenez JF, Gonzalez-Maeso J. Hallucinogens and Serotonin 5HT2A Receptor Mediated Signaling Pathways. Current Topics in Behavioral Neuroscience. 2018; 36: 45-73
Liechti ME. Modern Clinical Research on LSD. Neuropsychopharmacology. 2017; 42: 2114-2127.
Murphy RJ, et al. MDLSD: study protocol for a randomised, double-masked, placebo-controlled trial of repeated microdoses of LSD in healthy volunteers. Trials. 2021; 22. https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05243-3
Murphy RJ, et al. Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled Trial. Biological Psychiatry. 28 March 2023. https://www.biologicalpsychiatryjournal.com/article/S0006-3223(23)01164-2/fulltext#gr2
Passie T, et al. The pharmacology of lysergic acid diethylamide: a review. CNS Neuroscience and Therapeutics. 11 Nov 2018. https://onlinelibrary.wiley.com/doi/10.1111/j.1755-5949.2008.00059.x

IPC Digital Health Brings Suite of Profitable New Services to Independent Pharmacy | Pharmacy Crossroads

Ashton Maaraba has spent 20 years bring exciting new products and services to independent pharmacy. Most of them deploying major new technological capabilities. Now he has taken the helm of IPC Digital Health. In this episode he outlines the 5 Pillars that form the foundation for IPC's continuing efforts to future proof pharmacy. Maaraba indicates that telehealth, remote patient monitoring, adherence programs, operational efficiency and new patient care services such lab testing will provide pharmacies with the ability to generate much needed non-dispensing or PBM dependent revenue.

Advocacy In Action | The PUTTcast

Legislative season may be winding down, but advocates are ramping up for education season!
 
Listen in as PUTTcast hosts Monique Whitney and Lauren Young welcome advocacy guru AIDS Healthcare Foundation's Associate Director of Advocacy, John Farina to the mic. From creative campaigns to the importance of educating legislative staff - effective advocacy never sleeps!

DiversifyRx with Dr. Lisa Faast | Sports Pharmacy Podcast

Guys how rare is it that we get TWO members of the Pharmacy Podcast Network combining our efforts to give YOU the best episode we can! We talk all pharmacy things! How business owners can improve their profit line NOW and even what the future outlook of pharmacy looks like. Dr. Lisa Faast is what she has deemed a "Pharmacy Badass"! I have to agree with her because she is pretty intuitive when it comes to independent pharmacy. She's out here trying to save our profession, y'all! Get tickets to their next event here: https://2023.pharmacyprofitsummit.com/2023-summit#open-popup I have been to a few of the "Pharmacy Profit Summits" and it will NOT disappoint! 

PGx Education History & Future Projection with Dave Kisor | PGX For Pharmacists

Dr. Dave Kisor, a professor and director of pharmacogenomics at Manchester University. He graduated from The Ohio State University College of Pharmacy in 1986 and completed a two-year fellowship in therapeutic drug monitoring/pharmacokinetics at OSU. Before he joined Manchester, Dave was professor of pharmaceutical sciences at Ohio Northern University after being a research scientist at Burroughs Wellcome Co/GlaxoWellcome. Dave has over 80 peer-reviewed publications including being the lead author on two pharmacogenomics textbooks. He is a past chair of the American Association of Colleges of Pharmacy (AACP) Pharmacogenomics Special Interest Group. Dave was named a Fellow of the American College of Clinical Pharmacology in 2017, and in 2021, along with Dr. Tom Smith, he received an AACP Innovations in PGx Teaching Award. His current research is related to PGx and opioid use disorder. Dave currently serves as co-chair of the Pharmacogenomics Global Research Network (PGRN) Education Committee and is Editor-In-Chief of Pharmacogenomics: Foundations, Competencies, and the Pharmacists’ Patient Care Process.

Titans for PBM Reform: Loretta Boesing & Antonio Ciaccia | PBM Reform

House Energy and Commerce Committee cleared a PBM bill that seems to contain more transparency loopholes and makes more limited policy tweaks to the drug supply chain middleman than the Senate HELP Committee’s bill, but the House-side legislation would pull back the curtain on specialty-drug reimbursement in a way the Senate version does not. Two titans of PBM Reform join us today, returning guest Antonio Ciaccia with 3 Axis Advisors and Loretta Boesing with Unite for Safe Medications update our PBM Reform Podcast listeners with the latest progression in PBM Reform. Reference: PBM Reform: Vertical Integration, Specialty Drug Tracking Among Differences In House v. Senate Billshttps://pink.pharmaintelligence.informa.com/PS148320/PBM-Reform-Vertical-Integration-Specialty-Drug-Tracking-Among-Differences-In-House-v-Senate-Bills 

Framework Focus Launch with Dr. Mark Fulton | Framework Focus

On this episode, we introduce Framework Focus, a brand-new podcast that connects the Long-Term Pharmacy ecosystem, hosted by FrameworkLTC's very own Dr. Mark Fulton. In this conversation, Mark shares with Todd a little bit about the podcast and what to expect in the months to come. He also previews the FrameworkLTC User Conference happening this Fall in Boston.

Expand Your Pharmacy Practice: Part 1 | Integra X Files

Integra X Files blog contributor Paul Baldwin joins us for a two-part conversation on how pharmacists can expand their practice. In Part 1, he discusses the history and potential of the pharmacy industry, the benefits of caregiving, and the role of pharmacists in healthcare innovation and progress.

LSD Part 1: History and Early Clinical Research | Neural Pharm Podcast

From Basel, Switzerland to the summer of love in San Francisco. What did we learn about LSD, and why did it fall out of favor in the US? Part 2 will explore what's next in research...
Audio Correction: Colby misspoke 4:15: meant to say “Methergine is used for postpartum hemorrhage after delivery,” said “hemorrhage after bleeding” (which of course is redundant and a mistake).
Article on Ergotamine association with the Salem Witch Trials (from the Outside Hustle, Colby’s other blog):
Blotter Art examples:
https://keseyblotterart.com/
References:
Bryant C, Clark J. “How LSD Works.” Stuff You Should Know [podcast] 5 May 2016.
Dyck E. LSD: a new treatment emerging from the past. CMAJ. 2015 Aug 4;187(14):1079–80. doi: 10.1503/cmaj.141358. Epub ahead of print. PMID: 26243813; PMCID: PMC4592308.
Dyck, E. (2006). ‘Hitting Highs at Rock Bottom’: LSD Treatment for Alcoholism, 1950–1970. Soc. Hist. Med. 19: 313-329. [PDF]
Gasser, P. et al. (2014). Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases. J. Nerv. Ment. Dis. 202: 513-520. [Full text]
Irwin, S. A., et al. (2013). Daily Oral Ketamine for the Treatment of Depression and Anxiety in Patients Receiving Hospice Care: A 28-Day Open-Label Proof-of-Concept Trial. J. Palliat. Med. 16: 958-965. [PDF]
Pollen M. “How to Change Your Mind: What the New Science of Psychedelics Teaches us About Consciousness, Dying, Addiction, Depression, and Transcendence.” Penguin Press. New York. 2018.
Sandison, R. A., et al. (1954). The therapeutic value of lysergic acid diethylamide in mental illness. J. Ment. Sci. 100: 491-507. [Summary]
Sandison, R. A. & Whitelaw, J. D. A. (1957). Further studies of the therapeutic value of lysergic acid diethylamide in mental illness. J. Ment. Sci. 103: 332-343. [Summary]
Sessa, B. (2008). Can psychedelic drugs play a role in palliative care? Eur. J. Pall. Care 15: 235-237. [PDF]
Simmons, J. Q., et al. (1966). Modification of Autistic Behavior with LSD-25. Am. J. Psych. 122: 1201-1211. [Summary]
Smart, R. G. & Storm, T. (1964). The Efficacy of LSD in the Treatment of Alcoholism. Quart. J. Alcohol 25: 333-338. [PDF]
Smith, C. M. (1958). A New Adjunct to the Treatment of Alcoholism: The Hallucinogenic Drugs. Quart. J. Alcohol 19: 406-417. [PDF]
Shroder T. “Apparently Useless: The Accidental Discovery of LSD. The Atlantic. 9 Sept 2014. Available at: https://www.theatlantic.com/health/archive/2014/09/the-accidental-discovery-of-lsd/379564/
Tanne, J. H. (2004). Humphrey Osmond. BMJ 328: 713. [Full text]
Vollenweider F. X. & Kometer, M. (2010). The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nature Rev. Neurosci. 11: 642-651. [PDF]